MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- PIRAMAL ENTERPRISES (pharmaceuticals)
- Latest 8 Quarter Result
PIRAMAL ENTERPRISES Quarterly Results (NCHP)
Here are the latest quarterly results of PIRAMAL ENTERPRISES. For more details, see the PIRAMAL ENTERPRISES financial fact sheet and PIRAMAL ENTERPRISES share price and chart. For a sector overview, read our pharmaceuticals sector report.
PIRAMAL ENTERPRISES Quarterly Results
| No. of Mths Qtr. Ending |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
3
Dec-20* |
3
Mar-21* |
3
Jun-21* |
3
Sep-21* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 38,057 | 33,410 | 29,373 | 33,018 | 31,686 | 34,016 | 29,087 | 31,055 | |
| Other income | Rs m | 1,413 | 2,396 | 655 | 376 | 962 | 1,644 | 1,029 | 1,281 | |
| Turnover | Rs m | 39,470 | 35,806 | 30,028 | 33,394 | 32,648 | 35,660 | 30,116 | 32,336 | |
| Expenses | Rs m | 15,099 | 34,386 | 11,419 | 13,019 | 12,777 | 16,237 | 13,589 | 15,514 | |
| Gross profit | Rs m | 22,958 | -976 | 17,955 | 20,395 | 19,103 | 17,779 | 15,348 | 14,012 | |
| Depreciation | Rs m | 1,664 | 1,429 | 1,346 | 1,394 | 1,416 | 1,453 | 1,491 | 1,534 | |
| Interest | Rs m | 14,417 | 12,953 | 11,046 | 11,558 | 10,117 | 9,365 | 9,850 | 9,632 | |
| Profit before tax | Rs m | 8,289 | -12,962 | 6,217 | 7,819 | 8,532 | 8,605 | 5,036 | 4,128 | |
| Tax | Rs m | 2,306 | 12,595 | 1,611 | 2,039 | 2,012 | 14,768 | 1,351 | 1,028 | |
| Profit after tax | Rs m | 5,983 | -25,557 | 4,606 | 5,781 | 6,520 | -6,163 | 3,685 | 3,100 | |
| Gross profit margin | % | 60.3 | -2.9 | 61.1 | 61.8 | 60.3 | 52.3 | 52.8 | 45.1 | |
| Effective tax rate | % | 27.8 | -97.2 | 25.9 | 26.1 | 23.6 | 171.6 | 26.8 | 24.9 | |
| Net profit margin | % | 15.7 | -76.5 | 15.7 | 17.5 | 20.6 | -18.1 | 12.7 | 10.0 | |
| Diluted EPS | Rs | 25.1 | -107.1 | 19.3 | 24.2 | 27.3 | -25.8 | 15.4 | 13.0 | |
| Diluted EPS (TTM) | Rs | NA | -47.0 | -43.5 | -38.5 | -36.2 | 45.0 | 41.2 | 29.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: PIRAMAL ENTERPRISES 1QFY22 Result Performance Review
More Pharmaceuticals Company Quarterly Results: SUN PHARMA AUROBINDO PHARMA CIPLA DR. REDDYS LAB LUPIN
Compare PIRAMAL ENTERPRISES With: SUN PHARMA AUROBINDO PHARMA CIPLA DR. REDDYS LAB LUPIN
Today's Market
Indian Indices End Flat Amid High Volatility; Maruti Suzuki & Tech Mahindra Among Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
Views on news
PIRAMAL ENTERPRISES 2020-21 Annual Report Analysis (Annual Result Update)
Oct 26, 2021 | Updated on Oct 26, 2021Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.
Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)
Oct 8, 2021The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.
PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY22); Net Profit Down 20.0% (Quarterly Result Update)
Aug 9, 2021 | Updated on Aug 9, 2021For the quarter ended June 2021, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (down 20.0% YoY). Sales on the other hand came in at Rs 29 bn (down 1.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)
Dec 16, 2021In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)
Dec 3, 2021As the new variant of Covid-19 emerges, keep an eye on these stocks.
More Views on NewsMost Popular
These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)
Jan 18, 2022Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.
Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)
Jan 18, 2022Tech Mahindra's acquisition of European IT-company fails to excite investors.
5 Hidden Tata Group Companies to Add to Your Watchlist (Views On News)
Jan 18, 2022Here's all you need to know about these five Tata group stocks that aren't as popular as the others.
4 'Digital India' Stocks to Add to Your 2022 Watchlist (Views On News)
Jan 28, 2022Digitisation is touching every aspect of our lives. As this megatrend picks up pace, there will be companies benefitting from it for years to come.
Insiders are Buying into these 6 Stocks Aggressively. More Details here... (Views On News)
Jan 19, 2022While promoter holding is an important parameter, it should not be the sole reason for buying a stock.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2022
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: How to Profit from Sensex 100,000
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
PIRAMAL ENTERPRISES SHARE PRICE
Jan 28, 2022 (Close)
TRACK PIRAMAL ENTERPRISES
- Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PIRAMAL ENTERPRISES
PIRAMAL ENTERPRISES 5-YR ANALYSIS
COMPARE PIRAMAL ENTERPRISES WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
FOLLOW
APP
EQUITYMASTER SUPPORTS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.